53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details
臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04830644 (ClinicalTrials.gov) | March 22, 2021 | 28/3/2021 | A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. | A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Iguratimod in Patients With Active Primary Sjogren's Syndrome. | Primary Sjögren Syndrome | Drug: Iguratimod;Drug: Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | NULL | Recruiting | 18 Years | 75 Years | All | 144 | Phase 2 | China |
| 2 | ChiCTR1900024642 | 2019-08-01 | 2019-07-19 | Clinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome | Clinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome | Primary Sjogren's Syndrome | Experimental group:Iguratimod+Prednisone;control group:HCQ+Prednisone; | Chongqing Hospital of Traditional Chinese Medcine | NULL | Recruiting | 18 | 65 | Both | Experimental group:30;control group:30; | N/A | China |
| 3 | ITMCTR1900002482 | 2019-08-01 | 2019-07-19 | Clinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome | Clinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome | Primary Sjogren's Syndrome | Experimental group:Iguratimod+Prednisone;control group:HCQ+Prednisone; | Chongqing Hospital of Traditional Chinese Medcine | NULL | Recruiting | 18 | 65 | Both | Experimental group:30;control group:30; | N/A | China |
| 4 | ChiCTR1900021345 | 2019-02-12 | 2019-02-16 | Effect of Iguratimod on Primary Sjogren's Syndrome | Observation of Iguratimod's Effect on Primary Sjogren's Syndrome, A randomized, double-blind, placebo-controlled trial | Primary Sjogren's Syndrome | Control group :Hydrochloroquine;Treatment group:Iguratimod; | Tianjin Medical University General Hospital | NULL | Recruiting | 18 | 75 | Both | Control group :30;Treatment group:30; | China | |
| 5 | NCT03023592 (ClinicalTrials.gov) | February 2017 | 15/1/2017 | Study of Iguratimod in Sjögren's Syndrome | A Preliminary Efficacy Study of Iguratimod in Patients With Sjögren's Syndrome | Sjogren's Syndrome | Drug: Iguratimod | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 75 Years | All | 30 | Phase 1/Phase 2 | China |